ATE556092T1 - Mittel zur diagnose und therapie von ctcl - Google Patents

Mittel zur diagnose und therapie von ctcl

Info

Publication number
ATE556092T1
ATE556092T1 AT01271393T AT01271393T ATE556092T1 AT E556092 T1 ATE556092 T1 AT E556092T1 AT 01271393 T AT01271393 T AT 01271393T AT 01271393 T AT01271393 T AT 01271393T AT E556092 T1 ATE556092 T1 AT E556092T1
Authority
AT
Austria
Prior art keywords
ctcl
diagnosis
therapy
agents
novel
Prior art date
Application number
AT01271393T
Other languages
English (en)
Inventor
Armand Bensussan
Laurence Boumselle
Martine Bagot
Allessandro Moretta
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of ATE556092T1 publication Critical patent/ATE556092T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01271393T 2000-12-18 2001-12-18 Mittel zur diagnose und therapie von ctcl ATE556092T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00403580 2000-12-18
PCT/EP2001/015417 WO2002050122A2 (en) 2000-12-18 2001-12-18 Means for the diagnosis and therapy of ctcl

Publications (1)

Publication Number Publication Date
ATE556092T1 true ATE556092T1 (de) 2012-05-15

Family

ID=8173990

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01271393T ATE556092T1 (de) 2000-12-18 2001-12-18 Mittel zur diagnose und therapie von ctcl

Country Status (9)

Country Link
US (4) US7399595B2 (de)
EP (1) EP1343822B1 (de)
JP (3) JP2004528824A (de)
AT (1) ATE556092T1 (de)
AU (2) AU2002219229B2 (de)
CA (1) CA2432036C (de)
DK (1) DK1343822T3 (de)
ES (1) ES2387969T3 (de)
WO (1) WO2002050122A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399595B2 (en) 2000-12-18 2008-07-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Means for the diagnosis and therapy of CTCL
EP2292264A3 (de) 2003-07-24 2012-12-19 Innate Pharma Methoden und Zusammensetzungen zur Erhöhung der Wirksamkeit von therapeutischen Antikörper unter Verwendung von Verbindungen, die NK-Zellen potenzieren
ES2534288T3 (es) 2004-08-03 2015-04-21 Innate Pharma Composiciones terapéuticas contra el cáncer que seleccionan como objetivo 4Ig-B7-H3
EP1831258B2 (de) 2004-12-28 2023-06-07 Innate Pharma S.A. Monoklonale antikörper gegen nkg2a
CN101300272B (zh) * 2005-10-14 2013-09-18 依奈特制药公司 用于治疗增生性病症的组合物和方法
ES2656359T3 (es) 2006-06-30 2018-02-26 Novo Nordisk A/S Anticuerpos anti-NKG2A y usos de los mismos
US7917085B2 (en) * 2007-11-09 2011-03-29 Research In Motion Limited System and method for blocking devices from a carrier network
CN101952317B (zh) 2008-01-24 2015-07-22 诺沃-诺迪斯克有限公司 人化抗-人nkg2a单克隆抗体
WO2009126804A2 (en) * 2008-04-11 2009-10-15 The Regents Of The University Of Colorado, A Body Corporate Expression of kir in human cancer cells as a biomarker for immuno-escape and cancer metastasis
ES2539045T3 (es) * 2009-01-19 2015-06-25 Innate Pharma Anticuerpos anti-KIR3D
US20120288499A1 (en) 2010-01-15 2012-11-15 Armand Bensussan Methods for diagnosis and treatment of cutaneous t cell lymphomas
US9224537B2 (en) 2011-05-31 2015-12-29 Indian Institute Of Technology Madras Electrode and/or capacitor formation
CA2838220C (en) 2011-06-17 2020-07-21 Novo Nordisk A/S Use of nkg2a antibodies for treatment of bone loss
US9024609B2 (en) * 2012-07-11 2015-05-05 Pai Capital Llc Circuit and method for providing hold-up time in a DC-DC converter
CA2881765C (en) * 2012-09-19 2024-02-13 Innate Pharma Kir3dl2 binding agents
US10246510B2 (en) 2012-09-19 2019-04-02 Innate Pharma KIR3DL2 binding agents
AU2014203896B2 (en) * 2013-01-07 2018-05-31 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cutaneous T cell lymphoma
WO2014124267A1 (en) * 2013-02-07 2014-08-14 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Method for diagnosis, prognosis and determination of treatment for cutaneous t-cell lymphoma
DK2958941T3 (da) * 2013-02-20 2019-06-24 Innate Pharma Forbindelse, der binder specifikt til kir3dl2, til anvendelse til behandling af perifert t-cellelymfom
US20160108122A1 (en) * 2013-05-23 2016-04-21 Idac Theranostics, Inc. Therapeutic or prophylactic agent for immunodeficiency virus infection
US20160130346A1 (en) * 2013-05-29 2016-05-12 Institut National De La Sante Et De La Recherche Medicale Kir3dl2 is a biomarker and a therapeutic target useful for respectively preventing and treating a subset of cutaneous and non-cutaneous peripheral t-cell lymphomas
CA2939204C (en) * 2014-03-14 2023-06-27 Innate Pharma Humanized antibodies with increased stability
CN109863175A (zh) 2016-10-21 2019-06-07 依奈特制药公司 用抗-kir3dl2药剂进行的治疗
JP7611834B2 (ja) 2019-01-22 2025-01-10 イナート・ファルマ・ソシエテ・アノニム Ｔ細胞リンパ腫の処置
CN117242093A (zh) 2021-04-05 2023-12-15 先天制药公司 免疫组织化学方法和kir3dl2特异性试剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2104526C1 (ru) * 1995-05-05 1998-02-10 Эммануил Маркович Коган Способ диагностики т-клеточных лимфом кожи
US7399595B2 (en) * 2000-12-18 2008-07-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Means for the diagnosis and therapy of CTCL

Also Published As

Publication number Publication date
JP2008289489A (ja) 2008-12-04
CA2432036C (en) 2018-05-01
EP1343822B1 (de) 2012-05-02
WO2002050122A2 (en) 2002-06-27
US20110151472A1 (en) 2011-06-23
EP1343822A2 (de) 2003-09-17
AU2002219229B9 (en) 2002-07-01
JP2008261875A (ja) 2008-10-30
US20050074761A1 (en) 2005-04-07
JP2004528824A (ja) 2004-09-24
CA2432036A1 (en) 2002-06-27
ES2387969T3 (es) 2012-10-04
US20080274468A1 (en) 2008-11-06
DK1343822T3 (da) 2012-08-13
AU1922902A (en) 2002-07-01
US20120329063A1 (en) 2012-12-27
WO2002050122A3 (en) 2003-04-10
US8268308B2 (en) 2012-09-18
AU2002219229B2 (en) 2007-12-20
US7919085B2 (en) 2011-04-05
US8518655B2 (en) 2013-08-27
US7399595B2 (en) 2008-07-15
JP5134445B2 (ja) 2013-01-30

Similar Documents

Publication Publication Date Title
AU1922902A (en) Novel means for the diagnosis and therapy of CTCL
BR0111125A (pt) Moléculas de ácido nucléico de nrg-2, polipeptìdeos, e métodos diagnóstico e terapêuticos
ATE465257T1 (de) Agonisten für den rezeptor des hepatozyten- wachstumsfaktors und deren anwendungen
BG66080B1 (bg) Заместени тиоацетамиди
NO20041917D0 (no) Spesifikke midler som binder humant angiopoietin-2
BR0011838A (pt) Elementos misturadores estáticos empilhados
SE9802729D0 (sv) Novel Compounds
DE602004014361D1 (de) Verwendung von oxazolidinon-chinolin-hybrid-antibiotika zur behandlung von anthrax und anderen infektionen
EP1505990A4 (de) Verfahren zur behandlung von hepatitis
DE60138715D1 (de) Tnf-rezeptor-ähnliche moleküle und deren anwendungen
EP1465990A4 (de) Gestutzes lysostaphin-molekül mit verbesserter staphylolytischer wirkung
ATE319439T1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
ES2168361T3 (es) Secuencias de adn para metaloproteasas de la matriz, su preparacion y empleo.
EP1423137A4 (de) Lipopeptid-stereoisomere, verfahren zu ihrer herstellung und nützliche zwischenprodukte
DE60115349D1 (de) Polymorphismen im Gen für den humanen organischen Anionentransporter C (OATP-C)
ATE483714T1 (de) Podophyllotoxine als antiproliferative mittel
DE60224667D1 (de) Perylenequinonen zur anwendung als sonosensitizer
ATE291586T1 (de) Humanes antibiotisches protein
ATE545421T1 (de) Pharmazeutisches präparat zur behandlung von parasitären tropenkrankheiten enthaltend diminazen-di-aceturat
ATE374260T1 (de) Asthma-assoziiertes gen
ATE251619T1 (de) 1,4-dioxacycloalkan-2-one und 1,4-dioxacycloalken-2-one
DE50215004D1 (de) Organische verbindungen mit biologischer wirkung als thrombinhemmer und ihre verwendung
ATE390435T1 (de) Zusammensetzungen und verfahren zur diagnose und behandlung von diabetes, insulinresistenz und dyslipidämie
BR0211533A (pt) Tratamento de dor crÈnica com 3-heterociclil- e 3-cicloalquil-3-ariloxipropanaminas